Increase/Decrease in Cash: The total change in cash for the company over the given period.
Novartis AG (NVS) had Increase/Decrease in Cash of $-4.56B for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$13.52B |
|
$3.16B |
|
$3.46B |
|
$10.06B |
|
$9.29B |
|
$4.24B |
|
$-396.00M |
|
$3.84B |
|
$3.84B |
|
$3.16B |
|
$3.16B |
|
$3.16B |
|
$3.16B |
|
$4.24B |
|
$5.44B |
|
1.91B |
|
1.92B |
|
$1.65 |
|
$1.65 |
|
| Balance Sheet Financials | |
$26.61B |
|
$10.65B |
|
$91.92B |
|
$118.53B |
|
$31.37B |
|
$37.45B |
|
$48.23B |
|
$79.61B |
|
$38.93B |
|
$-28.10B |
|
$38.93B |
|
-- |
|
| Cash Flow Statement Financials | |
$3.68B |
|
$-11.74B |
|
$3.58B |
|
$11.44B |
|
$6.88B |
|
|
Increase/Decrease in Cash |
$-4.56B |
$303.00M |
|
$-6.20B |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.85 |
|
-- |
|
-- |
|
0.49 |
|
1.16 |
|
74.42% |
|
31.31% |
|
31.31% |
|
-- |
|
28.39% |
|
23.34% |
|
$3.33B |
|
-- |
|
-- |
|
-- |
|
0.11 |
|
0.55 |
|
1.41 |
|
63.90 |
|
8.11% |
|
-11.23% |
|
2.66% |
|
4.13% |
|
-- |
|
$1.74 |
|
$1.92 |
|